Samples of drugs used in diabetes, hypertension, allergies, infections found substandard in quality tests

Jaipur: Samples of five drugs were found to be of substandard quality upon testing and analysis conducted by the Commissionerate, Food Safety and Drug Control (CFSDC).

On Wednesday, the CFSDC issued directions to all the district drug controllers in the state to ensure that the stocks of these drugs are no longer consumed. They were instructed to provide appropriate safeguards to consumers by withdrawing the available stock and taking action as per the provisions of the Drugs & Cosmetics Act 1940.

A senior CFSDC official said, samples of Levocetirizine Dihydrochloride Tablets (Wincet-L), manufactured by M/s YL Pharma of Baddi in Solan district, Himachal Pradesh, were found to be of substandard quality. The drug was sold as an antihistamine used to treat symptoms associated with various allergic conditions.

A sample of Voglibose tablets 0.3 mg (DULCOVOG-0.3), manufactured by M/s Lifecare Neuro Products Ltd of Dharampur in Himachal Pradesh, failed the quality test. The drug is used as an antidiabetic medication to manage type 2 diabetes mellitus.
A sample of Ofloxacin Tablets IP 200 mg (OFWIN-200), manufactured by M/s YL Pharma of Baddi in Solan, failed the quality test. The drug is a fluoroquinolone antibiotic used to treat a variety of bacterial infections.

A sample of Telmisartan and Amlodipine Tablets IP (Telpin-A), manufactured by India M/s Maskon Life Sciences Pvt. Ltd in Bhagwanpur of Roorkee, was found to be of substandard quality. The drug is used as a combination medication to treat high blood pressure (hypertension) in adults.

The CFSDC tested a sample of Cefixime Oral Suspension manufactured by M/s Agron Remedies Pvt. Ltd of Sarverkhera, Uttarakhand, which failed the quality test. It is used as an antibiotic medication to treat a variety of bacterial infections, particularly in children and adults who have difficulty swallowing pills.

Related Posts

Over 9,000 deaths due to respiratory diseases in Delhi

New Delhi:  The national capital recorded 9,211 deaths due to respiratory diseases in 2024, up from 8,801 in 2023, continuing an upward trend seen over the past few years, according…

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

New Delhi:  The demand for nebulisers, inhalers and respiratory medicines for children has surged sharply in Delhi during winter months, with chemists reporting spikes of up to 60 per cent…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over 9,000 deaths due to respiratory diseases in Delhi

Over 9,000 deaths due to respiratory diseases in Delhi

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab